Literature DB >> 8544901

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

J C Breitner1, K A Welsh, M J Helms, P C Gaskell, B A Gau, A D Roses, M A Pericak-Vance, A M Saunders.   

Abstract

Factors that modify onset of Alzheimer's disease (AD) may be revealed by comparing environmental exposures in affected and unaffected members of discordant twin pairs or sibships. Among siblings at high risk of AD, sustained use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with delayed onset and reduced risk of AD. After adjustment for use of NSAIDs, there was minimal effect on onset with reported history of any of three common illnesses (arthritis, diabetes, or acid-peptic disease). However, independent of exposure to NSAIDs, onset was unexpectedly delayed in those reporting extended use of histamine H2 blocking drugs. Randomized clinical trials will be needed to affirm the utility of these drugs for prevention, but the present findings may have implications for pathogenesis: because NSAIDs block the calcium-dependent postsynaptic cascade that induces excitotoxic cell death in NMDA-reactive neurons, and because histamine potentiates such events, excitotoxicity may deserve additional investigation in AD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8544901     DOI: 10.1016/0197-4580(95)00049-k

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  81 in total

1.  Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo.

Authors:  M T Heneka; T Klockgether; D L Feinstein
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

2.  Neuronal overexpression of cyclooxygenase-2 does not alter the neuroinflammatory response during brain innate immune activation.

Authors:  Saba Aid; Nishant Parikh; Sara Palumbo; Francesca Bosetti
Journal:  Neurosci Lett       Date:  2010-05-06       Impact factor: 3.046

Review 3.  Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease.

Authors:  P L McGeer
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

Review 4.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Sudeep Gill; Ali Samii
Journal:  BMJ       Date:  2003-07-19

Review 5.  Neuronutrition and Alzheimer's disease.

Authors:  Balenahalli N Ramesh; T S Sathyanarayana Rao; Annamalai Prakasam; Kumar Sambamurti; K S Jagannatha Rao
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors.

Authors:  M J Smit; R Leurs; A E Alewijnse; J Blauw; G P Van Nieuw Amerongen; Y Van De Vrede; E Roovers; H Timmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

7.  Pharmacotherapy in the treatment of Alzheimer's disease: an update.

Authors:  Brian E Leonard
Journal:  World Psychiatry       Date:  2004-06       Impact factor: 49.548

8.  Association Between Proton Pump Inhibitor Use and Cognitive Function in Women.

Authors:  Paul Lochhead; Kaitlin Hagan; Amit D Joshi; Hamed Khalili; Long H Nguyen; Francine Grodstein; Andrew T Chan
Journal:  Gastroenterology       Date:  2017-07-18       Impact factor: 22.682

Review 9.  Anti-inflammatory agents in Alzheimer's disease.

Authors:  Paul S Aisen
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

10.  The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse.

Authors:  G P Lim; T Chu; F Yang; W Beech; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.